Talk:Amantadine/Archive 1

Removal of external links
I removed all of the external links in the External links section, for these reasons: ~ Danelo 23:19, 2 August 2007 (UTC)
 * The Washington Post article should have been a reference; I added it to the Refs section and added inline citations to it.
 * Endo Pharmaceuticals prescribing information was already listed as a reference. There's no need to include it twice.
 * MedicineNet.com's info on Amantadine had some potentially useful information, but nothing beyond what the article would have if it was a Featured Article (see External_links). Also, there is a lot, perhaps an objectionable amount, of advertising on MedicineNet.com.
 * The Journal of Infectious Diseases article should was already listed as a reference, so I changed the referencing to an inline citation so it appeared in the References section.

WikiProject class rating
This article was automatically assessed because at least one WikiProject had rated the article as start, and the rating on other projects was brought up to start class. BetacommandBot 07:51, 10 November 2007 (UTC)

"In fiction"/"In popular culture"/etc. section
Fans of the TV show House are eager to add to this article the fact that amantadine plays a crucial role in this year's season finale. I consider myself a House fan, but is that information really notable enough to put into this article here? --Hnsampat (talk) 14:44, 25 May 2008 (UTC)
 * I guess you are referring to a US television show? I dont think that Wikipedia would be more useful if this local trivia were added, although many in the US might find it interesting or amusing.  But you can always add the item and see what other editors think.--Smokefoot (talk) 15:04, 25 May 2008 (UTC)
 * I actually think the information does not belong here. Somebody had added it in and I removed it, after which it was added again and I removed it again. Now, it's been added yet again and I wanted to raise the issue here before removing the info. --Hnsampat (talk) 19:00, 26 May 2008 (UTC)


 * It absolutely does not belong there, since it's such a minor focus (1 episode). Even the reference to House in the vicodin article is borderline at best. Bockbockchicken (talk) 19:18, 27 May 2008 (UTC)


 * I don't think it is appropriate content either. It's simply not relevant.  -- Ed (Edgar181) 19:56, 27 May 2008 (UTC)

What about hepatitis C?
According to the HCV article, Amantadine is being investigated as an adjunctive treatment, along with Ribavirin and interferon.--74.124.187.76 (talk) 00:50, 25 June 2009 (UTC)

cocaine cravings
A couple of pharmacists have told me that Amantadine has properties that reduce an addict’s craving for cocaine. Does anyone have any links to support this concept? So far I have found: http://ajp.psychiatryonline.org/cgi/content/full/157/12/2052. Is this usable? 208.125.237.242 (talk) 16:57, 10 September 2010 (UTC)

Rating
On request, I'm rating this article as High importance because it's a first-in-class. It's a good Start article; could be easily made into a C article if information on contraindications, pharmacokinetics and interactions were added. Please consider removing the dosage information (see MOSMED). Hope I could help. Cheers, ἀνυπόδητος (talk) 20:09, 19 November 2010 (UTC)

Severe traumatic brain injury
http://www.nejm.org/doi/full/10.1056/NEJMoa1102609?query=TOC

MBVECO (talk) 21:47, 1 March 2012 (UTC)

Reorder?
Just for consistency with other durg articles, shouldn't MOA be a little closer to the top? — Preceding unsigned comment added by 137.43.182.249 (talk) 22:41, 25 April 2012 (UTC)

Plans for edits in summer of 2019
Hello all, I'm planning on working on amantadine's article. Below please find my working plan and goals. Thank you in advance, and thanks for what's already here.

Goal: By 2 August 2019, provide concise, accessible, current information to medical professionals and patients about the drug amantadine including:


 * mechanism of action
 * side effects
 * contraindications
 * uses (approved and off label)
 * pharmacologic interactions (males and females if studies are done)
 * resistance concerns

The above information is relevant if you're going to take the drug to understand risks and benefits. The above information is important if you're a medical professional to limit risks, educate patients, and obtain a good working understanding of the pharmacokinetics, dynamics, mechanism of action, and current approved/off label uses. Also considering generic v brand and costs in US/abroad

Thinking out loud with SMART:

Specific: improve and/or add the above 7 categories for readability (for patient, professional, and learner) and completeness. Measurable: 7 goal topics → 7 categories to monitor and make progress Attainable: Extremely confident it's possible to make progress on 1 area; remain confident it's possible to address all 7 in time frame. Also by laying out the goals and intentions in writing on the talk page, it may still help improve the article Relevant: this article will be relevant for patients/loved ones/providers of people with Parkinsonian symptoms; also for people who may get the flu and need to know about viral resistance. It's listed on wikiprojects medicine, pharm, neuroscience, chemical, viruses (5!). Time bound: one month, broken out weekly with smaller contributing goals.

More specifically I'll look at:
 * citations and ensure they are secondary, preferentially open source, and up to date
 * originality/distinction from the sources
 * use of jargon/doctor speak
 * links (do they work, are they the most up to date)
 * adding a section about drug interactions

Hbultra (talk) 16:12, 9 July 2019 (UTC)

Peer-review Osmosis Wikipedia editing course summer 2019
Hi Hbultra, great work on editing/improving this page. I particularly want to congratulate you on adding 21(!) references, a vital part of improving Wikipedia articles.

Lead: The lead is clear and summarises the main points of the article concisely. Although there were a couple sentences were an "as" or "the" were missing so I added those in.

Chemical Structure: Does this need to be a separate section? Just comparing to the amphetamine page the last paragraph of the lead seems to contain similar information. Or if it does, I will reformat it now as a proper heading as at the moment it seems like an afterthought added in after the contents table. The content of this section is to the point and referenced well.

Apart from the "Chemical structure" portion the article is organised nicely and flows in a coherent manner. One suggestion/question for organisation would be if a "Drug interaction" section would be a good addition? Again, just using the amphetamine page as a guide.

Medical uses: Parkisons- maybe move the last sentence about the common combo of drugs in front of the sentence about the specific symptoms it treats? Seems like the flow from: it can be used alone or in combo... A common combo is levodopa and amantadine then the symptoms would be smoother. The cochrane review's own conclusion states that there wasn't enough evidence to make a conclusion on safety or efficacy, does this review need to be here/ does it add value to the section? The WHO report seems to be more helpful in general.

Influenza A- great section that is easy to follow and explains resistance but a reference to the current WHO guidelines mentioned is necessary if possible. Does the solitary sentence about the Cochrane review add much value to this section? Although it is a more recent source (2014) than the earlier cited WHO one (2010-11), if a reference is added to current WHO guidelines then the only advantage of the Cochrane one (recency) is no longer.

Off-label uses: slight more description, or a section in the Mechanism of action about off-label uses would be an informative improvement.

Contraindications: great addition to the sections. Could be improved by an explanation of why it is contraindicated in ESRF, or the contraindication of live-attenuated vaccines whilst using amantadine.

Adverse effects: great additions to this section, very strong section overall, looking at the amphetamine page maybe dividing the AEs into Physical and Psychological could be an improvement.

MOA- this section has been labelled that it relies too much on primary sources, which still seems the case. Additionally there are a couple [citation needed] flags that should be addressed.

Overall I think invaluable additions have been made to this article over the past month, especially in structure and referencing. As always there is room for improvement, these areas seem minor and achievable. Reading over your work-plan, you have addressed most of the 7 categories you chose to focus on, the only one that hasn't been covered was pharmacologic interactions. Your plan is a great tool for any Wikipedian who is keen on further improving this article.

Thank you for all your great work! Tkguv (talk) 09:08, 27 July 2019 (UTC)

Re: peer review
Thanks for a thorough review. Thanks also for bringing the framework of amphetamine's article. I agree completely about adding the information about the why for contraindications; they've been added. Chemical section broken out for clarity and organization.

My next area of focus would be to expand on the off label uses, including proposed mechanisms of actions; countries where amantadine is used for the off-label indication. Veterinary misuse and history sections require some re-write for clarity and to improve sources.

Regarding the Cochrane, WHO, USFDA statements: my thought was to include the latest statements from various governing bodies. Most studies I read agree there is mild or minimal benefit for parkinsonian symptom management; all agree do not use amantadine for flu A anymore. I did not note much variation in recommendations for Parkinsons disease. Is the theme of presenting the latest conglomerate findings more confusing than helpful still?

November 2020 Plan for Edits with Wikipedia Editing Course
Hello everyone,

I plan on working on the Amantadine article over the course of the next month. Thank you for the work that has already be done and the foundation that you all have laid. My plan for improvement of the article is laid out below. I welcome your feedback and I am looking forward to collaborating with you all.

By November 20, 2020 I plan to make the following changes detailed below.

I will be adding more detailed and current information to the following sections: •	Chemical structure •	Contraindications •	Medical uses: Will expand to include more detailed information about influenza A resistance. I may consider making Influenza A resistance a stand-alone section and include more detail on mechanism of resistance/history. •	Off-label use (subheading): This section is missing off-label use in TBI recovery that has been strongly supported in literature. I will also investigate current studies on the use of Amantadine in Hep C and reducing cocaine cravings (noted earlier in the talk section). I may consider adding a whole new section on current research. •	Mechanism of action: Plan to add MOAs as related to off-label uses •	Adverse Effects: Will be expanded to offer more in-depth information on the biomolecular mechanisms of adverse effects

To improve organization, I will add subcategories to the following sections: •	Adverse effects •	Mechanism of action •	Interactions

To improve readability, I will: •	Limit the use of medical jargon •	Use the Hemingway App to provide concise information •	Ensure that the text links are redirecting properly •	Remove many of the primary resources and replace them with up to date and preferentially open source secondary and tertiary references, primarily in the Mechanism of action section, which is flagged for relying too heavily on primary resources

I will decrease the coverage of: •	The Veterinary Misuse section which sites an article in the Washington Post as a reference. This section will need to be reduced and replaced with a less biased and more global appraisal of the development of influenza A resistance to amantadine.

Thank you in advance for your contributions. I am looking forward to working with you all to make improvements to this very important article!

By November 20, 2020 I plan to make the following changes detailed below.

Anicm1 (talk) 02:14, 30 October 2020 (UTC)

Wiki Education Foundation-supported course assignment
This article was the subject of a Wiki Education Foundation-supported course assignment, between 26 October 2020 and 20 November 2020. Further details are available on the course page. Student editor(s): Anicm1.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 17:10, 17 January 2022 (UTC)

Wiki Education Foundation-supported course assignment
This article was the subject of a Wiki Education Foundation-supported course assignment, between 8 July 2019 and 3 August 2019. Further details are available on the course page. Student editor(s): Hbultra. Peer reviewers: Tkguv.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 13:58, 16 January 2022 (UTC)